ARCHIVE
OF OLDER REPORTS AND DEVELOPMENTS
(Before
January 2001)
JANUARY 2001:
Interferon Appears to Slow
Progression, cancer & death in this Japanese Study of Patients with
Compensated Cirrhosis
Prevention
of hepatocellular carcinoma in patients with chronic active hepatitis
C and cirrhosis
with PDF of entire article
(1/31/2001)
Capravirine (new NNRTI
for salvage) Clinical Trials Restricted
Drug Restricted
in Patients Until Additional Safety Evaluation Resolved
What is vasculitis?
(1/29/2001)
Increased mitochondrial
toxicity with ribavirin in HIV/HCV coinfection
(1/29/2001)
Biopsy Is Required To Evaluate Liver Disease Severity
and Decide When To Begin Therapy
The Histologic Spectrum of Chronic Hepatitis C in Patients
with Repeatedly Normal ALT (Alanine Aminotransferase): Does Liver Biopsy
Make a Difference?
(1/28/2001)
Pharmacokinetics
on Two Pegylated Interferons Reported at AASLD 1999
(1/23/2000)
NY Gay Black Men Hit
Hard by AIDS
(01/25/2001)
Peg Intron
FDA Approved
First
Pegylated Interferon Approved for Marketing in the United States
Schering Press Release
(01/24/2001)
FDA Approves Hepatitis
C Therapy: Peg Intron Pricing
By THE ASSOCIATED PRESS
(01/24/2001)
Age-related response
to interferon alfa treatment in women vs men with chronic hepatitis
C virus infection: women 39 years or less of age respond better
to HCV treatment than men and women older than 40 years
Kyushu University Hospital
(01/24/2001)
Discontinuing Prophylaxis
for Opportunistic Infections
from Jules Levin
(01/18/2001)
Discontinuing Pneumocystis
carinii Prophylaxis
Editorial from
The New England Journal of Medicine -- January 18, 2001 -- Vol. 344,
No. 3
(01/18/2001)
Osteopenia in
HIV Infection
Written for NATAP by Andrew Carr, MD
(01/15/2001)
FDA Hearing,
January 11th, 2001, on Salvage Studies:
FDA Antiviral Panel
on January 11 Endorses 16-Week Viral Endpoints for HIV Salvage Studies
and FDA Sends Additional Messages
By Mark Mascolini
New
Drug Study Design, Toxicities, Resistance Profiles & Interactions
Editorial from Jules Levin, NATAP
Brief Summary:
16 WEEK STUDY
DATA FOR FDA APPROVAL;
DRUG TOXICITIES; NEW STUDY DESIGNS FOR TREATMENT-EXPERIENCED
PATIENTS & SALVAGE SITUATIONS
Written by Jules Levin
(01/15/2001)
Efavirenz plasma levels can predict treatment failure and
central nervous system side effects in HIV-1-infected patients
Reported
in the current issue of AIDS
also in full PDF
version
(01/15/2001)
The Role of Liver Biopsy in Chronic Hepatitis C
in full PDF version
BIOPSY STILL REQUIRED
(01/15/2001)
Association of Severe Insulin Resistance With Both Loss
of Limb Fat and Elevated Serum Tumor Necrosis Factor Receptor Levels in
HIV Lipodystrophy also in full PDF
version.
(01/10/2001)
AASLD
Report On HCV Therapy Toxicities
Hemoglobin
Decreases from Combination HCV Therapy including Ribavirin
(01/08/2001)
When To Begin Therapy:
Glasgow
& Contrasting Retrovirus Data Presentations
Fifth International Congress on Drug Therapy
in HIV Infection - October 22-26, 2000 , Glasgow, Scotland, UK
Written
for NATAP by W. David Hardy, M.D.
Retrovirus &
Glasgow studies: Initial Response To Therapy Based on CD4 & Viral
Load Likelihood of Virologic Failure (500 copies/ml)
Written by Jules Levin
(01/05/2001)
Interferon-alpha
induced thyroid dysfunction: three clinical presentations and a review
of the literature
(01/02/2001)
Osteonecrosis (avascular necrosis) in HIV:
A Case-Control Study
with:
Background on Lipids and Corticosteroids and Avascular Necrosis
(01/01/2001)
Fatigue Affecting
People With Liver Disease
(01/01/2001)